Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 11/20 | 0.62 |
| ▸ | MC5R | P33032 | 1/20 | 0.51 |
| ▸ | MC3R | P41968 | 1/20 | 0.51 |
| ▸ | MC1R | Q01726 | 1/20 | 0.51 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069671 | 0.92 | MC4R (0.73) | MC4RMC5RMC3RMC1R | |
| SCHEMBL18133537 | 0.90 | MC4R (0.64) | MC4RMC5RMC3RMC1R | |
| SCHEMBL18133436 | 0.88 | MC4R (0.56) | MC4RMC5RMC3RMC1R | |
| SCHEMBL46876 | 0.87 | MC4R (0.64) | MC4RMC5RMC3RMC1R | |
| SCHEMBL15078532 | 0.83 | MC4R (0.63) | MC4RMC5RMC3RMC1R | |
| SCHEMBL47093 | 0.79 | MC4R (0.69) | MC4RMC5RMC3RMC1R | |
| SCHEMBL15078534 | 0.79 | MC4R (0.65) | MC4RMC5RMC3RMC1R | |
| SCHEMBL47107 | 0.79 | MC4R (0.74) | MC4RMC5RMC3RMC1R | |
| SCHEMBL15078535 | 0.78 | MC4R (0.64) | MC4RMC5RMC3RMC1R | |
| SCHEMBL10069672 | 0.78 | MC4R (0.57) | MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | UNIVERSITE DE MONTREAL (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2013-06-27 | — | — | US | disclosed |
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2013-06-27 | — | — | US | disclosed |
| WO-2012003576-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Université de Montréal (CA) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165426-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | MC4R 1/4885MC5R 2/4885MC3R 4/4885 |
| US-20160296507-A1 | IMIDAZOPYRIDINE, IMIDAZOPYRIMIDINE AND IMIDAZOPYRAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC1R | MC4R 1/4885MC5R 2/4885MC3R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.